Analysts Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Target Price at $40.88

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been assigned an average rating of “Hold” from the ten ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $41.25.

AGIO has been the topic of several research analyst reports. Citigroup upped their price target on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. JPMorgan Chase & Co. lifted their price objective on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday. Bank of America boosted their target price on Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Finally, HC Wainwright upped their target price on Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th.

Insider Activity

In other news, insider Sarah Gheuens sold 30,000 shares of the business’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the transaction, the insider owned 54,645 shares of the company’s stock, valued at approximately $1,665,579.60. The trade was a 35.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of AGIO. T. Rowe Price Investment Management Inc. purchased a new position in Agios Pharmaceuticals in the 4th quarter worth approximately $25,000. Assetmark Inc. increased its holdings in shares of Agios Pharmaceuticals by 37.9% in the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 362 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Agios Pharmaceuticals during the 1st quarter valued at $40,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at $49,000. Finally, Eurizon Capital SGR S.p.A. bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth $72,000.

Agios Pharmaceuticals Trading Up 1.0%

Shares of NASDAQ:AGIO opened at $32.27 on Monday. The company has a 50 day moving average of $34.75 and a 200 day moving average of $31.01. The stock has a market cap of $1.93 billion, a P/E ratio of -4.60 and a beta of 0.58. Agios Pharmaceuticals has a 12 month low of $22.24 and a 12 month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.The firm had revenue of $44.75 million during the quarter, compared to analysts’ expectations of $26.39 million. On average, equities analysts forecast that Agios Pharmaceuticals will post -6.12 earnings per share for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.